Paper39746751
RNA editing in disease: mechanisms and therapeutic potential.
Tamizkar KH and 1 other. RNA, 2025. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. RNA editing in disease: mechanisms and therapeutic potential. Papers, record 39746751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39746751
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| RNA Editing | Major topic |
| Humans | |
| Adenosine Deaminase | |
| Inosine | |
| Adenosine | |
| Animals |
Source PubMed
References106
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25456137 | The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. | Cell Rep | 2014 | https://conductscience.org/library/papers/25456137 | PubMed |
| 2 | 34569891 | Site-directed RNA editing: recent advances and open challenges. | RNA Biol | 2021 | https://conductscience.org/library/papers/34569891 | PubMed |
| 3 | 10438602 | The importance of internal loops within RNA substrates of ADAR1. | J Mol Biol | 1999 | https://conductscience.org/library/papers/10438602 | PubMed |
| 4 | 35850307 | RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS. | J Biol Chem | 2022 | https://conductscience.org/library/papers/35850307 | PubMed |
| 5 | 38128529 | Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes. | Cell Metab | 2024 | https://conductscience.org/library/papers/38128529 | PubMed |
| 6 | 2434241 | A developmentally regulated activity that unwinds RNA duplexes. | Cell | 1987 | https://conductscience.org/library/papers/2434241 | PubMed |
| 7 | 31772029 | Cardiac valve involvement in ADAR-related type I interferonopathy. | J Med Genet | 2020 | https://conductscience.org/library/papers/31772029 | PubMed |
| 8 | 35859175 | ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. | Nature | 2022 | https://conductscience.org/library/papers/35859175 | PubMed |
| 9 | 2704740 | A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. | Proc Natl Acad Sci U S A | 1989 | https://conductscience.org/library/papers/2704740 | PubMed |
| 10 | 30849393 | ADAR1: A New Target for Immuno-oncology Therapy. | Mol Cell | 2019 | https://conductscience.org/library/papers/30849393 | PubMed |
| 11 | 28388405 | Trade-off between Transcriptome Plasticity and Genome Evolution in Cephalopods. | Cell | 2017 | https://conductscience.org/library/papers/28388405 | PubMed |
| 12 | 25555396 | Dynamic response of RNA editing to temperature in Drosophila. | BMC Biol | 2015 | https://conductscience.org/library/papers/25555396 | PubMed |
| 13 | 27643693 | Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières Syndrome and Beyond. | Neuropediatrics | 2016 | https://conductscience.org/library/papers/27643693 | PubMed |
| 14 | 11041852 | Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. | Biochemistry | 2000 | https://conductscience.org/library/papers/11041852 | PubMed |
| 15 | 10698941 | RNA recognition by a Staufen double-stranded RNA-binding domain. | EMBO J | 2000 | https://conductscience.org/library/papers/10698941 | PubMed |
| 16 | 35145313 | Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. | Nat Biotechnol | 2022 | https://conductscience.org/library/papers/35145313 | PubMed |
| 17 | 23001123 | Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. | Nat Genet | 2012 | https://conductscience.org/library/papers/23001123 | PubMed |
| 18 | 14615479 | Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. | J Biol Chem | 2004 | https://conductscience.org/library/papers/14615479 | PubMed |
| 19 | 36457700 | Filamin A pre-mRNA editing modulates vascularization and tumor growth. | Mol Ther Nucleic Acids | 2022 | https://conductscience.org/library/papers/36457700 | PubMed |
| 20 | 27595325 | Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. | Nat Med | 2016 | https://conductscience.org/library/papers/27595325 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42548802 | ADAR1 regulates radiosensitivity in ESCC through cIAP2-NF-κB signaling and C16orf46 editing. | iScience | 2026 | https://conductscience.org/library/papers/42548802 | PubMed |
| 42328436 | RNA variation as the driver of genomic efficiency and phenotypic complexity. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42328436 | PubMed |
| 42310695 | A cytoplasmic index for quantifying immune-related A-to-I RNA editing. | Genome Biol | 2026 | https://conductscience.org/library/papers/42310695 | PubMed |
| 42222368 | RNA editing in Parkinson's disease: emerging mechanisms, translational potential, and current challenges. | Front Neurosci | 2026 | https://conductscience.org/library/papers/42222368 | PubMed |
| 41742325 | Stunning Intricacies of RNA Editing Complexes RECC, RESC, and REH2C: Functional Organization, Developmental Regulation, and Evolutionary History in Kinetoplastid Protists. | Wiley Interdiscip Rev RNA | 2026 | https://conductscience.org/library/papers/41742325 | PubMed |
| 41090155 | Gene and RNA Editing: Revolutionary Approaches to Treating Diseases. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41090155 | PubMed |
| 41075184 | Cromolyn as a novel pharmacophore of the Zα domain of the RNA-editing enzyme ADAR1p150. | Protein Sci | 2025 | https://conductscience.org/library/papers/41075184 | PubMed |
| 40671518 | ADARs: pleiotropy in function, versatility in application. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40671518 | PubMed |
| 39858624 | ADAR Therapeutics as a New Tool for Personalized Medicine. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/39858624 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39746751
GET https://conductscience.org/api/papers/v1/39746751/references?page=2